it is a third line treatment in those in whom other treatments are not tolerated the drug is administered by infusion intravenously it was developed by savient pharmaceuticals it was approved in the united states in 2010 after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue the european medicines agency ema granted marketing authorization in 2013 for treatment of disabling tophaceous gout in 2016 this authorization was ended in europe it is an option for the 3 of people with gout who are intolerant to other medications pegloticase is given as an intravenous infusion every two weeks and has been found to reduce uric acid levels in this population it is likely useful for tophi but has a high rate of side effects about 40 of people develop resistance to the medication over time in individuals with glucose 6 phosphate dehydrogenase deficiency pegloticase may precipitate a severe life threatening hemolysis with methemoglobinemia it is therefore contraindicated in such individuals pegloticase may also show immunogenicity pegloticase is a recombinant porcine like uricase similarly to rasburicase it metabolises uric acid to allantoin this reduces the risk of precipitates since